-
1.发明授权公开(公告)号：US09353186B2
公开(公告)日：2016-05-31
申请号：US14123517
申请日：2012-05-31
申请人： Christoph Freiberg , Christiane Otto , Lars Linden , Axel Harrenga , Mark Trautwein , Simone Greven , Andreas Wilmen
发明人： Christoph Freiberg , Christiane Otto , Lars Linden , Axel Harrenga , Mark Trautwein , Simone Greven , Andreas Wilmen
IPC分类号： C07K16/28 , A61K39/395 , A61K45/06 , A61K39/00
CPC分类号： C07K16/2869 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/3015 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody blocks prolactin receptor-mediated signalling.
摘要翻译： 中和催乳素受体抗体Mat3和抗原结合片段，含有它们的药物组合物及其用于治疗或预防由催乳素受体介导的良性疾病和适应症的用途，例如子宫内膜异位症，子宫腺肌症，非激素雌性避孕，良性乳腺疾病和 乳腺，泌乳抑制，良性前列腺增生，肌瘤，高血压和正常泌乳素脱发，以及联合激素治疗中的联合抑制乳腺上皮细胞增殖和治疗和预防抗雌激素抵抗性乳腺癌。 该抗体阻断催乳素受体介导的信号传导。
-
2.发明申请公开(公告)号：US20140141003A1
公开(公告)日：2014-05-22
申请号：US14123517
申请日：2012-05-31
申请人： Christoph Freiberg , Christiane Otto , Lars Linden , Axel Harrenga , Mark Trautwein , Simone Greven , Andreas Wilmen
发明人： Christoph Freiberg , Christiane Otto , Lars Linden , Axel Harrenga , Mark Trautwein , Simone Greven , Andreas Wilmen
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395
CPC分类号： C07K16/2869 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/3015 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody blocks prolactin receptor-mediated signalling.
摘要翻译： 中和催乳素受体抗体Mat3和抗原结合片段，含有它们的药物组合物及其用于治疗或预防由催乳素受体介导的良性疾病和适应症的用途，例如子宫内膜异位症，子宫腺肌症，非激素雌性避孕，良性乳腺疾病和 乳腺，泌乳抑制，良性前列腺增生，肌瘤，高血压和正常泌乳素脱发，以及联合激素治疗中的联合抑制乳腺上皮细胞增殖和治疗和预防抗雌激素抵抗性乳腺癌。 该抗体阻断催乳素受体介导的信号传导。
-
公开(公告)号：US20130272968A1
公开(公告)日：2013-10-17
申请号：US13514992
申请日：2010-11-18
申请人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
发明人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
IPC分类号： A61K39/395 , A61K45/06
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2866 , C07K16/2869 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： The present invention is directed to the neutralizing prolactin receptor antibody 006-H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
摘要翻译： 本发明涉及中和催乳素受体抗体006-H08以及其成熟形式，以及抗原结合片段，含有它们的药物组合物及其在治疗或预防良性病症和由催乳素受体介导的适应症中的用途 子宫内膜异位症，子宫腺肌症，非激素女性避孕，良性乳腺疾病和乳腺疾病，哺乳期抑制，良性前列腺增生，纤维瘤，高血压和正常泌乳素脱发，联合激素治疗联合抑制乳腺上皮细胞增殖。 本发明的抗体阻断催乳素受体介导的信号传导。
-
公开(公告)号：US20120321632A1
公开(公告)日：2012-12-20
申请号：US13514991
申请日：2010-11-18
申请人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
发明人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2866 , C07K16/2869 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The composition of the invention blocks prolactin receptor-mediated signaling.
摘要翻译： 本发明涉及含有一种或多种中和催乳素受体抗体和抗原结合片段的药物组合物，以及它们在治疗或预防由催乳素受体介导的良性疾病和适应症的用途，例如子宫内膜异位，子宫腺肌症，非激素雌性避孕 ，良性乳腺疾病和乳腺疾病，哺乳期抑制，良性前列腺增生，肌瘤，高血压和正常泌乳素脱发，以及联合激素治疗中的抑制乳腺上皮细胞增殖的联合治疗。 本发明的组合物阻断催乳素受体介导的信号传导。
-
公开(公告)号：US09241989B2
公开(公告)日：2016-01-26
申请号：US13514996
申请日：2010-11-18
申请人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
发明人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
IPC分类号： A61K39/395 , C07K16/28 , A61K45/06 , A61K39/00
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2866 , C07K16/2869 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
摘要翻译： 本发明涉及中和催乳素受体抗体005-C04及其成熟形式，以及抗原结合片段，含有它们的药物组合物及其用于治疗或预防由催乳素受体介导的良性疾病和适应症的用途，例如 作为子宫内膜异位症，子宫腺肌症，非荷尔蒙女性避孕，良性乳腺疾病和乳腺疾病，哺乳期抑制，良性前列腺增生，肌瘤，高血压和正常泌乳素脱发，联合激素治疗联合抑制乳腺上皮细胞增殖。 本发明的抗体阻断催乳素受体介导的信号传导。
-
公开(公告)号：US09649374B2
公开(公告)日：2017-05-16
申请号：US13514992
申请日：2010-11-18
申请人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
发明人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
IPC分类号： A61K39/395 , A61K39/00 , C07K16/00 , C07K16/28 , A61K45/06
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2866 , C07K16/2869 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： The present invention is directed to the neutralizing prolactin receptor antibody 006-H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
-
公开(公告)号：US20130129739A1
公开(公告)日：2013-05-23
申请号：US13514996
申请日：2010-11-18
申请人： Christiane Ottto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
发明人： Christiane Ottto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder , Andrea Eicker , Andreas Wilmen
IPC分类号： C07K16/28
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2866 , C07K16/2869 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
摘要翻译： 本发明涉及中和催乳素受体抗体005-C04及其成熟形式，以及抗原结合片段，含有它们的药物组合物及其用于治疗或预防由催乳素受体介导的良性疾病和适应症的用途，例如 作为子宫内膜异位症，子宫腺肌症，非荷尔蒙女性避孕，良性乳腺疾病和乳腺疾病，哺乳期抑制，良性前列腺增生，肌瘤，高血压和正常泌乳素脱发，联合激素治疗联合抑制乳腺上皮细胞增殖。 本发明的抗体阻断催乳素受体介导的信号传导。
-
公开(公告)号：US20130171147A1
公开(公告)日：2013-07-04
申请号：US13514993
申请日：2010-11-18
申请人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder
发明人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder
IPC分类号： C07K16/28
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2866 , C07K16/2869 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： The present invention is directed to the neutralizing prolactin receptor antibody 002-H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
摘要翻译： 本发明涉及中和催乳素受体抗体002-H06和抗原结合片段，含有它们的药物组合物及其用于治疗或预防由催乳素受体介导的良性病症和适应症的用途，例如子宫内膜异位症，子宫腺肌症， 激素女性避孕，良性乳腺疾病和乳腺疾病，哺乳期抑制，良性前列腺增生，纤维瘤，高血压和正常泌乳素脱发，联合激素治疗联合抑制乳腺上皮细胞增殖。 本发明的抗体阻断催乳素受体介导的信号传导。
-
公开(公告)号：US20120315276A1
公开(公告)日：2012-12-13
申请号：US13514994
申请日：2010-11-18
申请人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder
发明人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder
IPC分类号： A61K39/395 , C12N15/13 , C12N15/63 , A61P17/14 , C12N1/19 , C12N1/21 , C12P21/02 , C07K16/28 , C12N5/10
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2866 , C07K16/2869 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： The present invention is directed to the neutralizing prolactin receptor antibody 002-H08, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
摘要翻译： 本发明涉及中和催乳素受体抗体002-H08和抗原结合片段，含有它们的药物组合物及其用于治疗或预防由催乳素受体介导的良性疾病和适应症的用途，例如子宫内膜异位症，子宫腺肌症， 激素女性避孕，良性乳腺疾病和乳腺疾病，哺乳期抑制，良性前列腺增生，纤维瘤，高血压和正常泌乳素脱发，联合激素治疗联合抑制乳腺上皮细胞增殖。 本发明的抗体阻断催乳素受体介导的信号传导。
-
公开(公告)号：US20130022606A1
公开(公告)日：2013-01-24
申请号：US13514995
申请日：2010-11-18
申请人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder
发明人： Christiane Otto , Siegmund Wolf , Christoph Freiberg , Axel Harrenga , Simone Greven , Mark Trautwein , Sandra Bruder
IPC分类号： A61K39/395 , C07H21/00 , A61P15/00 , A61P13/08 , A61P17/14 , C12P21/02 , A61P15/14 , C12N15/63 , C12N5/10 , C12N1/19 , C12N1/21 , C07K16/28 , A61P15/18
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2866 , C07K16/2869 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： The present invention is directed to the neutralizing prolactin receptor antibody 006-H07, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.
摘要翻译： 本发明涉及中和催乳素受体抗体006-H07和抗原结合片段，含有它们的药物组合物及其用于治疗或预防由催乳素受体介导的良性病症和适应症的用途，例如子宫内膜异位症，子宫腺肌症， 激素女性避孕，良性乳腺疾病和乳腺疾病，哺乳期抑制，良性前列腺增生，纤维瘤，高血压和正常泌乳素脱发，联合激素治疗联合抑制乳腺上皮细胞增殖。 本发明的抗体阻断催乳素受体介导的信号传导。
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.036 秒)
